Yes. With the continued consolidation, the top 4 specialty pharmacies have over 70% of the revenue market share. This makes it a buyers market. PBMs, most of whom are owned by the aforementioned large specialty pharmacies, continue to put a strain on the cash flow of the independent operators. There is also tremendous uncertainty with reimbursements on drugs. Essentially how are drugs priced at the point of sale. All of this has lead to declining valuations. Large Strategic buyer may spend 20% of revenue, while a Financial Buyer may pay between 5 – 6X. This is down from 25% of revenue and between 6 – 7X just in 2017 (based on internal transactional comp data)